Kawamata et al. found that spinal cannabinoid receptor 1 (CB1) activation by the CB1 agonist arachidonyl-2-chloroethylamide reduced bone cancer-related spontaneous and movement-evoked pain with a dose-dependent pattern [186]. This evidence concerns the gene CNR1 and bone neoplasm.